NCT00004699已完成不适用
Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
OBJECTIVES:
I. Determine the dose of recombinant human insulin-like growth factor I that minimizes or decreases the need for exogenous glucose support without causing hypoglycemia.
详细描述
PROTOCOL OUTLINE: This is a dose escalation study. Patients receive an escalating dose of recombinant human insulin-like growth factor I (IGF-I). IGF-I is given subcutaneously twice a day. The dose of IGF-I is increased each day for 4 days. Glucose is administered intravenously, when necessary, to prevent hypoglycemia.
Following the study treatment patients resume prior medication and may undergo surgery.
Completion date provided represents the completion date of the grant per OOPD records
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 3 Weeks 至 3 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 DeficiencyInsulin-Like Growth Factor-1 DeficiencyGrowth DisordersNCT00125190Ipsen45
已完成
不适用
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With HyperinsulinismHyperinsulinismNCT00004825FDA Office of Orphan Products Development10
已完成
不适用
Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's SyndromeWerner's SyndromeNCT00004815National Center for Research Resources (NCRR)1
已完成
3 期
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) DeficiencyGrowth DisordersInsulin-Like Growth Factor-1 DeficiencyNCT00125164Ipsen137
已完成
1 期
IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 DeficiencyShort StatureNCT02636270Children's Hospital Medical Center, Cincinnati7